Efficacy and safety of sema in non-diabetic obese adults: A systematic review and meta-analysis
Monitor weight, glycaemic control and side effects
105 The sequential dose-ranging, placebo-controlled, double-blinded safety study in biopsy-proven NASH patients with advanced fibrosis (Brunt stage 3) revealed no difference in adverse effects when GR-MD-02 single or three weekly repeated doses of 2, 4 or 8 mg/kg was used
Normalization was performed by assessing total DNA using Quanti-iT PicoGreen (Life Technologies, Gaithersburg, MD, USA)
Noom: Behavior meets biology Combines psychology-backed coaching with multiple GLP-1 prescription options
Gastrointestinal adverse events, including diarrhoea, nausea, and vomiting, were consistently the most common side effects reported across all dose groups in the phase 2 trial